Introduction
Current US 1 and European 2 acute coronary syndrome (ACS) guidelines recommend potent P2Y 12 -receptor inhibition with prasugrel or ticagrelor for 1 year in ACS patients managed with percutaneous coronary intervention (PCI). Landmark analyses have shown that the greatest benefits of potent antiplatelet agents are seen early, when the risk of ischaemic complications is highest, [3] [4] [5] [6] whereas bleeding risk is a major issue during the chronic treatment phase. 3, 4 Those differential risk patterns as well as clinical and socio-economic factors 7 have fuelled interest in strategies of a step-wise de-escalation 8 of dual antiplatelet treatment (DAPT), preferring the use of potent P2Y 12 inhibitors only during the early phase of treatment. In real-life scenarios, switching antiplatelet agents and especially a de-escalation of P2Y 12 -inhibitor treatment is commonly practiced. 7, [9] [10] [11] Recent smaller studies 9, 12 have provided conflicting results on outcomes of ACS patients following a non-guided and uniform approach of deescalation for P2Y 12 -inhibitor treatment. An International Expert Consensus on Switching Platelet P2Y 12 Receptor-Inhibiting Therapies was published just recently, 13 highlighting the clinical relevance of this subject and illustrating the need for guidance and standardization in switching of antiplatelet drugs.
In the randomized multicentre TROPICAL-ACS trial, 14, 15 we recently identified and established a guided de-escalation regimen with an early switch from prasugrel to clopidogrel as an effective alternative treatment strategy in invasively managed ACS patients. However, patient's age is a major determinant of outcomes after PCI in general, 16, 17 and especially in conjunction with the use of P2Y 12 -receptor inhibitors during and after PCI. 6, 18 Therefore, it seems mandatory to assess whether patients' outcomes following de-escalation of antiplatelet treatment may differ in relation to age. Herein, we present the results of a pre-specified analysis of the TROPICAL-ACS cohort assessing clinical outcomes in younger vs. elderly ACS patients with uniform prasugrel vs. guided DAPT de-escalation.
Methods
Study design and patients TROPICAL-ACS was an investigator-initiated, randomized, parallelgroup, open-label, assessor-blinded, and multi-centre trial in ACS patients undergoing PCI. The trial was conducted at 33 European sites (ClinicalTrials.gov identifier: NCT01959451). 14, 15 An independent data safety monitoring board (DSMB) oversaw the trial and it was monitored by an external service provider (Münchner Studienzentrum, Munich, Germany). The study was conducted in accordance with the principles of the Declaration of Helsinki and it was approved by the institutional ethics committee of each participating site, and by the associated competent national agencies. For this trial, biomarker positive ACS patients aged > _18 and < _80 years were enrolled after successful PCI. A history of transient ischemic attack (TIA) or stroke and need for anticoagulation were key exclusion criteria. More details on in-and exclusion criteria have been published previously. 14 With respect to the investigation on age and outcomes, the study protocol pre-specified age-dependent analyses for clinical events of the trial. A cut-off value for the age of 70 years was outlined in the protocol to distinguish between younger (age < _70 years) and elderly (age >70 years) patients.
Randomization and study groups
Acute coronary syndrome patients in this trial were randomized prior to discharge in a 1:1 fashion to the two study groups of either (i) DAPT deescalation guided by platelet function testing (PFT) or (ii) a uniform treatment with prasugrel (control group).
During the study period of 12 months, the control group patients were scheduled for prasugrel treatment (5 or 10 mg/d) according to guideline recommendations.
1,2 Guided de-escalation group patients received a post-discharge treatment consisting of 1 week prasugrel treatment followed by 1 week clopidogrel treatment (75 mg/d) and a PFT on clopidogrel 2 weeks after hospital discharge. Based on testing results in the guided de-escalation group, patients were either switched back to prasugrel, when a status of high-platelet reactivity (HPR) was detected, whereas patients with sufficient platelet inhibition (no HPR) continued clopidogrel. Study group related treatment was planned to start on the day after discharge and study drugs for the first 14 days post-discharge were packed and provided by the pharmacy department of the Klinikum der Universität München.
Follow-up procedures and platelet function testing
Two weeks after discharge all patients had an outpatient visit that included blood sampling for PFT with the Multiplate analyser (Roche Diagnostics, Rotkreuz, Switzerland). Details of this whole-blood based method have been published previously 14, 19, 20 and a status of HPR for this assay was defined according to the current consensus document of the Working Group on HPR by an ADPtest aggregation value of > _46 U. 19, 20 In the guided de-escalation group, testing results determined the further course of treatment. For observational purposes and to achieve equal conditions in both study groups, patients in the control group were also admitted to perform PFT. Of note, results obtained in this group had no influence on the further course of treatment. Further on, patients were contacted by phone call at 30 days, 6 months, and 12 months after randomization. This was done to explore study endpoints or adverse events with collection of source data for independent event adjudication and to assess adherence over time for the assigned antiplatelet therapy. 
Study endpoints
The primary study endpoint was a combined endpoint consisting of death from cardiovascular causes, myocardial infarction (MI), 21 
Statistical analysis
All age-dependent analyses presented here were performed on intention-to-treat basis. For the primary analysis, patients were stratified to younger (< _70 years) and elderly (>70 years) patients, as it was prespecified in the protocol of the trial. The effect of the intervention was first tested in univariate Cox-regression models, separately in the two pre-specified age categories (ACS patients < _70 years vs. >70 years 
Results

Study population
Between December 2013 and May 2016, 2610 eligible ACS patients with successful PCI were enrolled in the TROPICAL-ACS trial at 33 sites in Europe. 14, 15 From this intention-to-treat population, 1306 patients were randomly assigned to the control group and 1304 to the guided de-escalation group. As reported in detail previously, 15 the 12 months follow-up rate was 96% and the adherence to protocol-mandated treatment was high with 94% in both study groups. As we pre-specified in the trial protocol, patients were stratified into two subsets according to age (< _70 years, further referred to as younger patients vs. >70 years, further referred to as elderly patients).
The group of younger patients contributed the majority of patients (n = 2240, 86%), whereas the 370 (14%) remaining subjects were elderly. Table 1 presents the baseline characteristics of the study population stratified by age and study groups. Baseline characteristics did not differ between the guided de-escalation vs. the control group for younger patients, except for a higher proportion of diabetics in the control group. Likewise, there were no differences between the study groups for elderly patients, except for haemoglobin levels that were slightly lower in the control group patients. Angiographic and procedural characteristics are summarized in Table 2 . They were equally distributed across study groups within the subsets of younger and elderly patients except for more left main interventions in the guided de-escalation group of elderly patients and a higher rate of bioresorbable vascular scaffold implantations in the control group of elderly patients. Among guided de-escalation patients, a status of HPR was noted in 436 younger vs. 75 elderly patients corresponding to a similar proportion of 39% from the intention-to-treat population in both groups (P = 0.87). In line with the label of the drug that recommends utilization of low-dose prasugrel (5 mg) in patients above 75 years of age, significant differences were seen between younger vs. elderly patients for the rate of low-dose prasugrel. Overall use of 5 mg prasugrel was very low (0.8%) in the subset of younger patients, while it was significantly higher (16%, P < 0.0001) in the elderly. Among the 176 elderly control group patients, 26% were on lowdose prasugrel, while this rate was only 8% in guided de-escalation group due to many good responders taking clopidogrel.
Clinical endpoints in pre-specified age subgroups (cut-off of 70 years)
A total of 213 events defining the primary endpoint of the trial were reported during the 12 months follow-up period. In younger patients with < _70 years, the combined primary endpoint occurred in 5.9% in the guided de-escalation and in 8.3% in the control group [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.51-0.96; P = 0.03, Figure 1A and Table 3 ]. The absolute risk reduction of 2.4% observed for the primary endpoint corresponds to a number needed to treat of 42. In elderly patients >70 years, 1 year absolute event rates for the primary endpoint were higher compared with younger patients (P < 0.0001). However, there were no differences between the guided de-escalation vs. control group (15.5% vs. 13 .6%, respectively; HR 1.17, 95% CI 0.69-2.01; P = 0.56, Figure 2A and Table 3 ).
The one-year incidence of the key secondary endpoint of BARC > _2 bleedings was numerically lower in the guided de-escalation group of younger patients [43 events (3.9%) vs. 63 events (5.6%), HR 0.69, 95% CI 0.47-1.02; P = 0.06; Figure 1B and Table 3 ], whereas no differences were found among elderly patients (10.8% vs. 9 .1%, respectively, HR 1.23, 95% CI 0.64-2.35; P = 0.54; Figure 2B and Table 3 ). No differences were observed for combined ischaemic events (cardiovascular death, MI, stent thrombosis, and stroke) between guided de-escalation and control groups in younger (2.1% vs 2.8%, HR 0.73, 95% CI 0.43- 1.25 ; P = 0.25, Figure 1C and Table 3 ) and elderly patients (4.6% vs. 5 .7%, HR 0.83, 95% CI 0.34-2.03; P = 0.68, Figure 2C and Table 3) . 
and interaction terms for ischaemic and bleeding events in younger and elderly subjects.
Exploratory analyses on age-dependent effects and guided dual antiplatelet treatment de-escalation
For exploring age-dependent effects of the intervention we undertook a number of analyses beyond the pre-specified cutoff of 70 years. A Cox proportional hazards model that included age as a continuous variable showed a significant interaction of age with treatment effects for the primary endpoint between study groups (P int = 0.02). A STEPP analysis revealed that an increasing risk reduction was observed in the primary endpoint by the decrease of age in patients ( Figure 3 ). An exploratory post hoc analysis for interaction testing revealed 57 years of age as an optimal cut-off for separating age categories regarding a possible net clinical benefit from guided DAPT de-escalation (P int = 0.03). Although this cut-off value of 57 years is close to the median age (59 years) of the study population, it provided a larger sample size of elderly subjects (n = 1424) for further analyses. Using this post hoc defined optimal cut-off value, guided DAPT deescalation resulted in a significant reduction in primary endpoint events in the guided de-escalation vs. the control group [23 (3.9%) vs. 46 (7.7%) events, HR 0.50, 95% CI 0.31-0.83; P = 0.006, Table 4 and Figure 4 ]. This overall benefit in the composite primary endpoint was largely driven by a significant reduction of bleeding in patients <57 years (HR 0.38, 95% CI 0.20-0.74; P = 0.004), whereas the risk of bleeding was similar in elderly patients randomized to guided de-escalation vs. control treatment (P int = 0.007, Table 4 ). The relative risk of ischaemic events did not differ below and above 57 years of age in randomized groups (P int = 0.85, Table 4) .
With the flanking age cut-off values of 57 and 70 years three subgroups of patients are generated and for the primary endpoint the increasing risk reduction by a decrease of age (see STEPP model, 
Discussion
The present pre-specified analysis from the TROPICAL-ACS trial is the first dedicated and comprehensive analysis on age-dependent effects during guided de-escalation of P2Y 12 -inhibitor treatment in an all-comers cohort of ACS patients. Investigating the impact of key variables like patient's age on clinical outcomes following DAPT deescalation seems mandatory, considering the high prevalence of switching between oral P2Y 12 inhibitors in the real world. [7] [8] [9] 13 The key findings of our study are that a net clinical benefit from guided DAPT de-escalation strategy may be achieved in younger patients and this benefit was driven by a reduction in bleeding complications. Exploratory analyses lend strong support to the finding that net clinical benefit is increased by decreasing age in ACS patients. Notably, although the elderly patients (>70 years) represented a smaller subset of the trial cohort, outcomes were comparable for guided deescalation vs. uniform prasugrel treatment, without any sign of a harm of this approach. Age-dependent differences were mostly triggered by the bleeding endpoints following guided DAPT deescalation, whereas ischaemic risk was not influenced in any of the investigated age-dependent subgroups. The group of younger ACS patients (< _70 years) constituted the majority (>80%) of subjects enrolled in TROPICAL-ACS, whereas patients in the study had a mean age of 59 years that is very similar to the average age of patients reported in the TRITON-TIMI 38 trial 6 and the contemporary TRANSLATE-ACS registry. 7 In this large group of younger subjects, DAPT could be safely de-escalated as combined ischaemic events were similar and even numerically lower when compared with uniform prasugrel treatment. The present outcome data on switching and de-escalation of P2Y 12 -inhibitor treatment in younger patients are reassuring and clinically useful as data from the TRANSLATE-ACS registry 7 highlighted that socioeconomic factors, being relevant also in middle-aged patients, are key drivers for switching from potent antiplatelet drugs to clopidogrel post-hospital discharge. Importantly, such results may only be obtained if the de-escalation is controlled by PFT as it was done in the TROPICAL-ACS trial, and it is still unknown whether uncontrolled de-escalation may provide similar results or not. While finding no safety concerns in younger ACS patients, we observed a net clinical benefit for guided de-escalation in this subgroup, which was mostly driven by a reduction in bleeding events. In particular minor BARC Type 2 bleeding events were reduced in younger patients, whereas major (BARC 3 or 5) bleeding complications were comparable between the two study groups. However, even minor bleeding events are associated with poor treatment compliance and increased healthcare costs related to hospital readmissions or consultation of a primary care physician. [25] [26] [27] [28] Thus, DAPT strategies that come along with a reduction in minor bleeding should have a positive impact on patients' compliance, outcomes, and treatment costs. Overall outcome results in younger patients are in line with data from the entire TROPICAL-ACS trial cohort, where we also observed numeric reductions in minor bleeding events following guided de-escalation. In fact, the significantly higher utilization (16%) of low-dose (5 mg/d) prasugrel in elderly subjects may be one reason for the observation that differences in bleeding risk were not prominent between guided de-escalation and control groups in the elderly, compared to younger patients with full-dose (10 mg/d) prasugrel treatment in the control arm.
The typical clinical setting in elderly ACS patients is often characterized by a high prevalence of multi-vessel disease, a frequent history of prior MI or revascularization and a number of comorbidities including diabetes, peripheral artery disease, and renal insufficiency. The subset of elderly patients (> _70 years) in TROPICAL-ACS resemble those assumptions. In line with prior studies in elderly ACS patients, 29 the overall event rates were high in our cohort and nearly doubled the event rates of younger patients for both bleeding and ischaemic complications. Study group comparisons in elderly patients showed similar outcomes regarding ischaemic complications including cardiovascular death (CVD), MI, ST, and stroke. Thus, results on ischaemic events suggest that DAPT can be safely de-escalated in the elderly whenever this is deemed necessary in these often frail and multi-morbid patients. However, one cannot expect a large reduction in bleeding in such a frail subgroup. A number of reasons may account for a lack of a significant reduction in bleeding risk following guided de-escalation in the elderly. First, the subset of elderly patients (>70 years) represents a small cohort of patients in our trial and it also excludes the very elderly (patients >80 years). Dedicated trials in larger cohorts of elderly and very elderly patients will be necessary and the ongoing and randomized Elderly-ACS 2 30 and POPular AGE 31 trials will provide important results on potent vs. standard also suggest that only minor differences were seen on the level of platelet inhibition between low-dose prasugrel vs. clopidogrel. Concerning baseline and procedural characteristics, the subset of elderly patients in TROPICAL-ACS was comparable to patients enrolled in the recent ANTARCTIC trial. 29 ANTARCTIC focused on elderly ACS patients and a low dose of prasugrel was chosen for all patients in the control group of the trial. As a results, the trial did not show any difference between 5 mg prasugrel and PFT-guided individualization of P2Y 12 -inhibitor therapy. Taking this into consideration, our findings confirm the results of the ANTARCTIC trial by finding similar event rates for both bleeding and ischaemia when a uniform treatment strategy was compared to an individualized DAPT approach in the elderly. Finally, risk profiles and triggers for adverse events are likely to differ in younger vs. elderly patients. Study results suggest that the relative benefit from guided de-escalation in younger subjects, mostly triggered by lower rate of bleeding events, may be explained by the lower rate of complex co-morbidities and a more direct link between antiplatelet potency and bleeding events in the younger population. Contrary, managing antithrombotic treatment in the elderly is complex and challenging. Due to the high rate of comorbidities both bleeding and ischaemic event rates are significantly higher in the elderly population and the link between antithrombotic treatment potency and outcomes is not as simple and direct as in younger ACS patients. 34 The TROPICAL-ACS trial exactly mirrors this situation with a significantly higher absolute risk of both bleeding and thrombotic events in the elderly. From a general point of view, the availability of different P2Y 12 -receptor inhibitors has generated new opportunities for physicians to Figure 3 Subpopulation treatment effect pattern plot for treatment group (the guided de-escalation vs. the control group) and covariate (age in years) interactions. The plotted hazard ratios across age subpopulations are based on primary endpoint comparisons across study groups. The red line represents the hazard ratios and the dotted lines represent the 95% confidence interval. The supremum P-value denotes the interaction term derived from subpopulation treatment effect pattern plot analysis.
Age and outcomes following guided de-escalation of antiplatelet treatment 35 Triggers may be diverse but certainly include significant cost savings by prescribing generic clopidogrel to the patients. Lower cost may be relevant for the individual patient but even more so for the entire healthcare system. 27 Beyond costs, the increased bleeding risk during chronic treatment with prasugrel 3 or ticagrelor 4 as well as non-bleeding side effects such as dyspnoea on ticagrelor represent common scenarios where DAPT de-escalation is considered. With respect to switching modalities and definitions, as they were outlined recently in an international consensus document 13 on this subject, this pre-specified analysis from the TROPICAL-ACS trial provides evidence for a guided and very early (<30 days) deescalation regimen with intra-class (prasugrel to clopidogrel and vice versa) switching of P2Y 12 inhibitors in ACS patients. We acknowledge some limitations related to our study. First, the pre-specified subgroup of patients aged >70 years was relatively small, which leads to broader confidence intervals for the studied endpoints. Upcoming dedicated trials will further elucidate this topic in elderly ACS patients. 30 ,31 Herein, we pre-specified a cut-off value of 70 years to define elderly patients. While this cut-off is arbitrary as any other cut-off value would be, it is in line with the definition of elderly patients in prior and ongoing randomized trials on elderly ACS patients undergoing PCI. 31 While the TROPICAL-ACS trial was powered to test for differences in a net clinical benefit endpoint in control vs. guided de-escalation study groups, our study was not powered for detecting differences in individual ischaemic endpoints. Further on, our study protocol mandated for choosing prasugrel and it remains unclear to what extent our findings can be extrapolated to younger vs. elderly patients receiving ticagrelor. Finally, very elderly patients (>80 years) were excluded from our trial and it remains unknown in how far guided DAPT de-escalation approach may benefit those patients.
In conclusion, potential benefits after guided de-escalation of P2Y 12 -inhibitor treatment in ACS patients after PCI are not uniform. A significant heterogeneity was found regarding patient's age with younger patients showing an increased net clinical benefit arising from a reduction in bleeding complications. Of note, treatment effects with respect to ischaemia were similar in all investigated subsets. These results suggest that guided de-escalation may be a safe and attractive alternative treatment concept for all ACS patients after PCI, while a significant benefit in bleeding may be achieved in younger patients.
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